NERVIANO MEDICAL SCIENCES ANNOUNCED CLINICAL TRIAL APPROVAL IN CHINA OF THE PARP INHIBITOR NMS-293 IN PATIENTS WITH ADVANCED SOLID TUMORS TODAY.
NMS Group
December 1, 2020

Nerviano Medical Science Srl, the NMS Group subsidiary specialized in research and development of innovative oncological drugs, today announced the recent approval of a phase I clinical study for its PARP inhibitor (NMS-03305293) by China National Medical Products Administration(NMPA). NMS-03305293, a second-generation PARP inhibitor with differential preclinical pharmacological properties will be trialed in Chinese patients with advanced/metastatic solid tumors (HER2 negative breast cancer, ovarian cancer, castration-resistant prostate cancer and pancreatic cancer) to observe its safety profile in this Phase I study.
“NMS Srl, along with its collaborators conducts numerous clinical studies all over the world of multiple innovative drugs” commented CEO Nanding Zhao of NMS Group, “but this is the first time that one of our drug candidates obtained the NMPA approval for clinical trial in China. We are working with a great partner dMed – a clinical research CRO based in Shanghai with highly experienced clinical trial team, and we hope that this first experience will soon be followed by many projects to directly benefit Chinese cancer patients. In this way, we could stimulate a strong acceleration to our development programs and move closer to our final goal – to improve the living conditions of patients all over the world.”
The Chairman of NMS Group, Andrea Agazzi expresses his satisfaction: “when we welcomed the new Chinese partners back in 2018, the wealth of their technical and scientific contribution was what I valued the most than that of financial. China is at the forefront in research and development of drugs today also in oncology. It hosts realities such as dMed that can bring value to our research, but it is also a complex country, where only the right collaboration would bring success. Our oncology R&D team at NMS Srl have been able to build an important partnership that I hope will be an example to the whole world of Italian research sector.”
###

About NMS Group
NMS Group is Italy’s largest innovative oncological R&D based pharmaceutical company. With more than 400 employees of which more than half are highly educated researchers dedicated to groundbreaking research and development. The NMS kinase inhibitor discovery platform as well as the antibody-conjugated payload platform are the driving forces of the group’s innovation, securing global recognition of NMS in personalized therapy. Entrectinib, discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now member of the Roche Group, who gained recent approvals for commercialization in all major markets. This is a further evidence of the value and competitiveness of the drug discovery platform at NMS Group.
The NMS Group has three subsidiaries: the first, NMS s.r.l. is a FIC / BIC focused, expert drug research and development company, with a robust pipeline of more than a dozen anti-cancer programs ongoing, three of which currently in early clinical stage of development. The other two subsidiaries Accelera and NerPharMa provide preclinical research services, and CDMO services respectively for local and international customers.

About dMed
dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. dMed is led by experts in China and the US who originated from leading multinational pharma companies and regulatory agencies. We are uniquely positioned to leverage and integrate China’s new regulatory framework, offer innovative drug development strategies, and help our clients expand globally by tapping into the world’s second largest pharmaceutical market. Our creative and flexible collaboration models will help Chinese and global innovative pharma companies effectively raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rate.
Our business covers consulting, regulatory affairs & strategy, early development & clinical pharmacology, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, clinical science & medical affairs, quality assurance and information solutions.
dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.
###